Bulging eyes. Blurry vision. A face in the mirror that suddenly looks unfamiliar. For many people living with Graves’ disease, Thyroid Eye Disease (TED) is an unexpected and unsettling twist. About 20% of patients with autoimmune thyroid conditions will experience symptoms that affect the muscles and fat around the eyes – some mildly annoying, others physically and emotionally debilitating.
Fortunately, TED is treatable.
With advances in both medication and surgical techniques, more treatment options exist today than were previously available. Whether you’re just noticing early discomfort or weighing your options after months of inflammation, this guide will walk you through the most current treatment options – what they do, when they work best, and how to match them to your symptom severity.
Recognizing Early Thyroid Eye Disease Symptoms
Early detection is key to stopping TED before it leads to long-term damage. Many patients first notice eye discomfort, irritation, or puffiness, but the signs can escalate quickly if not addressed. TED typically progresses in two phases: the active phase, when inflammation is present and changing rapidly, and the inactive phase, when the disease stabilizes but leaves behind structural changes.
Common thyroid eye disease symptoms to watch for include:
- Eye pain, particularly with movement
- Excessive tearing or dry, gritty eyes
- Swelling in the upper or lower eyelids
- A wide-eyed appearance or retracted eyelids
- Double vision when looking up, down, or to the side
- Blurred vision or pressure behind the eyes
Some patients may also experience headaches or light sensitivity. While these symptoms may seem manageable at first, they can significantly interfere with daily life and should be evaluated by an eye care specialist familiar with TED.
Medical vs. Surgical Treatment Approaches
Treatment for TED depends heavily on the phase of the disease and the severity of symptoms. In the active phase, the focus is on reducing inflammation and preventing vision loss. In the inactive phase, treatment shifts toward correcting damage caused by prolonged swelling and tissue changes.
Medical treatment is almost always the first step. It includes a range of therapies, from anti-inflammatory medications to immunosuppressants, depending on how aggressively the disease is progressing. Surgery is usually considered after the inflammation has resolved or if there is a risk of permanent vision loss.
The most effective treatment plans are tailored to the individual and often involve input from an endocrinologist, ophthalmologist, and oculoplastic surgeon. This team-based approach helps ensure all aspects of TED—visual function, appearance, and overall health—are managed appropriately.
Anti-Inflammatory Therapies: Steroids and Beyond
Corticosteroids are one of the most common first-line treatment for moderate to severe TED in the active phase. They work by rapidly reducing inflammation and pressure behind the eyes. Intravenous steroids like methylprednisolone are often preferred for their effectiveness, especially in urgent or vision threatening cases.
Oral steroids may also be used, though they tend to act more slowly and come with systemic side effects such as weight gain, high blood pressure, and mood changes. To minimize complications, doctors typically use steroids for a short period and then taper off once the symptoms are under control.
Steroids don’t cure TED, but they serve as a temporizing measure to help manage symptoms. Once inflammation is reduced, other therapies are often introduced to maintain results and support long-term recovery.
According to the American Academy of Ophthalmology, corticosteroids are best suited for the early active phase of TED when inflammation is high and changes occur quickly.
Radiation Therapy: When Is It Appropriate?
Orbital radiation is a low-dose therapy that targets the immune cells causing inflammation behind the eyes. Though not a first-line treatment, it can be very effective when used appropriately. The therapy is delivered over several sessions and works best when paired with steroids for short-term symptom control.
Radiation therapy is most often recommended for patients with moderate TED who have not responded well to medications or who cannot tolerate high-dose steroids. It is beneficial for addressing double vision and restricted eye movement caused by swelling of the extraocular muscles.
Side effects are generally mild and may include temporary skin irritation or dry eyes. Though long-term risks are still being studied, orbital radiation remains a safe and targeted option for patients needing additional relief in the active phase.
Immunomodulatory Medications and Biologics
Advances in immunotherapy have transformed the treatment landscape for TED. Rather than simply reducing inflammation, these medications aim to alter the disease at the immune system level.
Teprotumumab, the first biologic FDA-approved specifically for TED, blocks a receptor called IGF-1R that contributes to tissue swelling and fibrosis. In clinical studies, many patients saw reduced eye bulging, improved double vision, and better quality of life in just a few months.
Other immunosuppressants like mycophenolate mofetil, rituximab, or tocilizumab may be used off-label in some instances, especially when Teprotumumab is not available or appropriate. These drugs work more broadly to reduce immune system activity and are typically used in combination with other therapies.
A clinical review published by the National Library of Medicine highlighted Teprotumumab’s ability to improve both functional and cosmetic outcomes in patients with moderate to severe TED.
When to Consider Orbital Decompression Surgery
Surgery becomes an option when TED has entered the inactive phase and symptoms remain disruptive. Orbital decompression is the most common procedure and involves removing bone and fat from the orbit to create more space behind the eye. This relieves pressure on the optic nerve and helps the eyes sit more naturally in the socket.
Surgery is usually considered for:
- Vision loss due to optic nerve compression
- Severe proptosis (eye bulging) causing discomfort or cosmetic concern
- Persistent double vision or exposure of the cornea
- Cosmetic asymmetry or psychosocial distress from eye appearance
The procedure is typically followed by additional surgeries to adjust the eyelids or realign the eye muscles if needed. Outcomes are generally excellent, especially when an experienced oculoplastic surgeon performs the surgery. Your medical team will help you weigh risks, benefits, and timing to build a strategy that supports both your health and your quality of life.
Thyroid Eye Disease Treatment FAQs
What is Thyroid Eye Disease and who can develop it?
Thyroid Eye Disease (TED), also known as Graves’ ophthalmopathy, is an autoimmune condition where the immune system attacks the tissues around the eyes. This can lead to inflammation, swelling, and symptoms ranging from mild discomfort to severe vision problems. While TED is most commonly associated with hyperthyroidism (Graves’ disease), it can also occur in people with an underactive thyroid (hypothyroidism) or even in those with normal thyroid function. TED is fundamentally an autoimmune disease—the eye symptoms are caused by the immune system attacking orbital tissues, which can happen independently of thyroid hormone levels.
What are the first-line treatments for mild Thyroid Eye Disease symptoms?
For many people with TED, especially those with mild symptoms, conservative management is the first step. This includes:
- Lubricating eye drops, gels, and ointments to relieve dryness and irritation
- Sunglasses to help with light sensitivity
- Eye patches to manage double vision
- Selenium supplements which may help improve mild eye symptoms and reduce inflammation due to their antioxidant properties
- Quitting Smoking to reduce the risk of the disease progressing
These conservative measures can provide significant relief during the early stages of TED. If symptoms persist or worsen, your medical team may recommend advancing to prescription medications or other therapies. Treatment is tailored to each individual based on symptom severity and disease phase.
How does treatment differ between the active and inactive phases of TED?
Treatment approach changes significantly depending on whether TED is in the active inflammatory phase or the inactive, stable phase. During the active phase, when inflammation is present and changing rapidly, the focus is on reducing inflammation and preventing vision loss through medications like corticosteroids, biologics, or immunosuppressants. In the inactive phase, when the disease has stabilized but left behind structural changes, treatment shifts toward correcting damage through surgical interventions. Surgery is typically considered only after inflammation has resolved. This phase-based approach ensures treatments are matched to what the disease is doing at that specific time, maximizing effectiveness while minimizing unnecessary interventions.
What surgical options are available for Thyroid Eye Disease and when are they needed?
Surgery is often considered during the inactive phase of TED to correct structural changes. Three main surgical procedures address different aspects of the condition:
- Orbital decompression surgery reduces bulging eyes (proptosis) and relieves pressure on the optic nerve, which is crucial in cases of vision loss
- Strabismus surgery corrects double vision caused by changes in the eye muscles
- Blepharoplasty (Eyelid surgery) addresses eyelid retraction or other eyelid abnormalities
These surgeries are usually performed sequentially, with orbital decompression first, followed by muscle adjustment, and finally eyelid correction if needed. Long-term follow-up after treatment is important to monitor for complications and adjust your care plan as needed. Your medical team will help determine the right timing and sequence based on your specific symptoms and goals.
English 
Spanish